ArticleJournal of general internal medicine2004
Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough.
Article in Journal of general internal medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Trial
- Clinical analyses of angiotensin-converting enzyme inhibitor users presenting with cough to a chest diseases outpatient clinic: A single-center retrospective study.The Journal of international medical research · 2026Article
- Racial and Ethnic Disparities in Hypertension: Barriers and Opportunities to Improve Blood Pressure Control.Current cardiology reports · 2023Review
- Article
- Very long-term follow-up data of non-ischemic idiopathic dilated cardiomyopathy after beta-blocker therapy: recurrence of left ventricular dysfunction and predictive value ofHeart and vessels · 2019Article
- Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium.Journal of thoracic disease · 2018Review
- An Exploratory Survey of Incorporation of Gender- and Sex-related Differences in the PharmD Curricula.Innovations in pharmacy · 2018Article
- Factors affecting the development of adverse drug reactions (Review article).Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2014Review
- Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study.Medical science monitor : international medical journal of experimental and clinical research · 2012Article
- Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials.Patient preference and adherence · 2012Article
- Zofenopril and incidence of cough: a review of published and unpublished data.Therapeutics and clinical risk management · 2011Article
- Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.Clinical pharmacology and therapeutics · 2010Article
- Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril.Pharmacoepidemiology and drug safety · 2010Article
- Angiotensin inhibition after myocardial infarction: does drug class matter?Journal of general internal medicine · 2006Article
- David Westfall Bates, MD: a conversation with the editor on improving patient safety, quality of care, and outcomes by using information technology. Interview by William Clifford Roberts.Proceedings (Baylor University. Medical Center) · 2005Article
- The place for ACE inhibitors.Journal of general internal medicine · 2004Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundAngiotensin-converting enzyme inhibitors are effective for many cardiovascular diseases and are widely prescribed, but cough sometimes necessitates their withdrawal.
objectiveTo develop and validate a model that predicts, by using information available at first prescription, whether a patient will develop cough within 6 months.
designRetrospective cohort study with derivation and validation sets.
settingOutpatient clinics affiliated with an urban tertiary care hospital. PATIENTS: Clinical data were collected from electronic charts. The derivation set included 1125 patients and the validation set included 567 patients.
interventionsNone. MEASUREMENTS: Angiotensin-converting enzyme inhibitor-induced cough assessed by predetermined criteria.
resultsIn the total cohort, 12% of patients developed angiotensin-converting enzyme inhibitor-induced cough. Independent multivariate predictors of cough were older age, female gender, non-African American (with East Asian having highest risk), no history of previous angiotensin-converting enzyme inhibitor use, and history of cough due to another angiotensin-converting enzyme inhibitor. Patients with a history of angiotensin-converting enzyme inhibitor-induced cough were 29 times more likely to develop a cough than those without this history. These factors were used to develop a model stratifying patients into 4 risk groups. In the derivation set, low-risk, average-risk, intermediate-risk, and high-risk groups had a 6%, 9%, 22%, and 55% probability of cough, respectively. In the validation set, 4%, 14%, 20%, and 60% of patients in these 4 groups developed cough, respectively.
conclusionsThis model may help clinicians predict the likelihood of a particular patient developing cough from an angiotensin-converting enzyme inhibitor at the time of prescribing, and may also assist with subsequent clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.